CNS Pharmaceuticals logo
CNS Pharmaceuticals
CNSP | NASDAQ
Chart Builder DCF Calculator
$3.48
+$0.59 (+20.42%)
At close: Nov 16, 2026, 4:00 PM ET
$3.60
+$0.12 (+3.45%)
After-hours: Nov 16, 2026, 5:54 PM ET

CNS Pharmaceuticals Company Profile

Company profile explained

Company Profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.

Key Executives

Name Position
Rami Levin Chief Executive Officer, President & Director
Eric Faulkner Chief Technology Officer
Steve O'Loughlin Chief Financial Officer
Dylan Wenke Chief Business Officer
E. Lynne Kelley Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 02, 2026 8-K Current Report
Aug 25, 2026 DEFA14A Filing
Aug 21, 2026 DEF 14A Filing
Aug 18, 2026 4 Filing
Aug 18, 2026 3 Filing
Aug 18, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 10-Q Quarterly Report
Jul 02, 2026 8-K Current Report
May 26, 2026 EFFECT Filing
View All SEC Filings ➞
CNS Pharmaceuticals
CNS Pharmaceuticals logo
Country United States
IPO Date Nov 8, 2019
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Rami Levin

Contact Details

2100 West Loop South Houston, Texas 77027 United States

Stock Details

Ticker Symbol CNSP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001729427
CUSIP Number 18978H508
ISIN Number US18978H5081
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.